IP Library Granted Patent US 9,839,679
Granted Patent B2
US 9,839,679 · App. 14/191,407 · Granted Dec 12, 2017

Methods of reducing extravasation of inflammatory cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,679
App. No.
14/191,407
Granted
Dec 12, 2017
Kind
B2
Abstract

A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.

Claims (5)

1. A method of reducing extravasation of leukocytes from blood vessels in a patient having central nervous system injury comprising administering into the blood vessel a composition comprising an effective amount of an enzyme that cleaves chondroitin sulfate proteoglycan selected from chondroitinase ABC I, chondroitinase ABC II, Hyaluronidase 1, Hyaluronidase 2, Hyaluronidase 3, Hyaluronidase 4, and combinations thereof.

2. The method of claim 1 , wherein the administration is by bolus injection, continuous infusion, or sustained release formulation.

3. The method of claim 1 , wherein the enzyme is administered at about 0.001 mg per kg to about 100 mg per kg body weight of the patient.

4. The method of claim 1 , wherein the central nervous system injury is spinal cord injury.

5. The method of claim 1 , wherein the composition further comprises one or more excipients selected from the group consisting of preservatives, buffers, solubilizers, antioxidants, and pharmaceutical adjuncts.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2016
From: GRUSKIN, ELLIOTT A.; TSENG, JACK L.; CAGGIANO, ANTHONY O.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 038986/0669 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →